230 related articles for article (PubMed ID: 29666296)
21. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
Bukowski RM; Kabbinavar FF; Figlin RA; Flaherty K; Srinivas S; Vaishampayan U; Drabkin HA; Dutcher J; Ryba S; Xia Q; Scappaticci FA; McDermott D
J Clin Oncol; 2007 Oct; 25(29):4536-41. PubMed ID: 17876014
[TBL] [Abstract][Full Text] [Related]
22. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.
Bergman D; Modh A; Schultz L; Snyder J; Mikkelsen T; Shah M; Ryu S; Siddiqui MS; Walbert T
J Neurooncol; 2020 Jun; 148(2):353-361. PubMed ID: 32444980
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
[TBL] [Abstract][Full Text] [Related]
24. Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.
Schnell O; Thorsteinsdottir J; Fleischmann DF; Lenski M; Abenhardt W; Giese A; Tonn JC; Belka C; Kreth FW; Niyazi M
J Neurooncol; 2016 Dec; 130(3):591-599. PubMed ID: 27599828
[TBL] [Abstract][Full Text] [Related]
25. [Preliminary clinical evaluations of bevacizumab for recurrent malignant glioma in Chinese patients].
Lu Y; Qi S; Ouyang H; Li Z; Yin Y; Shi J; Qiu X; Mo Y
Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(15):1165-8. PubMed ID: 24924716
[TBL] [Abstract][Full Text] [Related]
26. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.
Wen PY; Schiff D; Cloughesy TF; Raizer JJ; Laterra J; Smitt M; Wolf M; Oliner KS; Anderson A; Zhu M; Loh E; Reardon DA
Neuro Oncol; 2011 Apr; 13(4):437-46. PubMed ID: 21297127
[TBL] [Abstract][Full Text] [Related]
27. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
[TBL] [Abstract][Full Text] [Related]
28. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
[TBL] [Abstract][Full Text] [Related]
29. Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with ("pseudo-randomized") treatment allocation by the health insurance provider.
Hofmann S; Schmidt MA; Weissmann T; Eyüpoglu I; Strnad A; Semrau S; Fietkau R; Putz F; Lettmaier S
J Neurooncol; 2020 Jun; 148(2):373-379. PubMed ID: 32409944
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma.
Fleischmann DF; Jenn J; Corradini S; Ruf V; Herms J; Forbrig R; Unterrainer M; Thon N; Kreth FW; Belka C; Niyazi M
Radiother Oncol; 2019 Sep; 138():99-105. PubMed ID: 31252301
[TBL] [Abstract][Full Text] [Related]
31. Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.
Chen WC; Qiu JT; Lai CH; Huang HJ; Lin CT; Chen MY; Chou HH; Huang KG; Chang TC
PLoS One; 2017; 12(5):e0175703. PubMed ID: 28467466
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors.
Goldlust SA; Cavaliere R; Newton HB; Hsu M; Deangelis LM; Batchelor TT; Gilbert MR; Lassman AB
J Neurooncol; 2012 Apr; 107(2):407-11. PubMed ID: 22203237
[TBL] [Abstract][Full Text] [Related]
33. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.
Wick W; Wick A; Weiler M; Weller M
Curr Neurol Neurosci Rep; 2011 Jun; 11(3):305-12. PubMed ID: 21279815
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab in Recurrent High-Grade Gliomas: A Canadian Retrospective Study.
Lim Fat MJ; Maurice C; Maganti M; Mason WP
Can J Neurol Sci; 2018 Jan; 45(1):56-61. PubMed ID: 29151389
[TBL] [Abstract][Full Text] [Related]
35. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).
Ding L; Liu K; Jiang Z; Chen Q; Zhou N; Liang Y; Gao H; Hong X; Wu H
Tumour Biol; 2015 Apr; 36(4):2491-9. PubMed ID: 25417899
[TBL] [Abstract][Full Text] [Related]
37. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
von Pawel J; Spigel DR; Ervin T; Losonczy G; Barlesi F; Juhász E; Anderson M; McCall B; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Reck M
Oncologist; 2018 Jun; 23(6):654-e58. PubMed ID: 29438092
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.
Tamura R; Tanaka T; Miyake K; Yoshida K; Sasaki H
Brain Tumor Pathol; 2017 Apr; 34(2):62-77. PubMed ID: 28386777
[TBL] [Abstract][Full Text] [Related]
40. [Anti-angiogenic therapy for malignant glioma].
Nagane M
Gan To Kagaku Ryoho; 2014 Feb; 41(2):141-7. PubMed ID: 24743191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
